65,437 trials
Schizophrenia
Primary: Number of Participants With Adverse Events (AE). — 35; 1 Participants
Displaced Forearm Fractures
Primary: Loss of Radius Fracture Reduction — 35; 35; 66; 66 participants — p=1.00
Thyroid Cancer
Primary: Progression-Free Survival (PFS) — 11.2; 4.0 months
Maraviroc Concentrations in Semen
Primary: Semen to Plasma Ratio of HIV Concentration During the Dosing Interval for Dar, Evr, Mar & Ral. — 0.20; 0.16; 0.92; 4.32 Inhibitory concentration ratio
Streptococcal Infection · Gram-positive Bacterial Infection · Bacterial Infection
Primary: Geometric Mean Concentrations (GMCs) of Antibodies in Mothers and Infants at Delivery/Birth — 5.39; 0.41; 4.37; 0.4 µg/mL
Vitamin B12 Deficiency
Primary: Change in Amount of Epogen Required — -16,572 unit/ml
Seizures
Primary: Pharmacokinetic Profile — 0.51 ml/min/kg
Smoking Cessation · Schizophrenia
Primary: Measurement and Treatment Research to Improve Cognition in Schizophrenia (MATRICS) Cognition Domains — 96; 95 units on a scale — p=<0.05
Migraine Disorders
Primary: Time-weighted Mean Arterial Pressure (Sumatriptan With Telcagepant Versus Sumatriptan Alone) — 89.0; 87.5 mmHg
Sedation · Endoscopy
Primary: Endoscopist's Satisfaction (Visual Analog Scale) About Sedation — 93; 83; 98; 87 units on a scale
Ileostomy - Stoma
Primary: Preference — 65; 35 percentage of participants
Systemic Lupus Erythematosus
Primary: Adverse Reaction (Leucopenia) — 6; 19 participants — p=<0.01
Smoking Cessation
Primary: Percentage of Change in Expired Air Carbon Monoxide (CO) at End of Week 2 — -0.52 percentage change
Sinus Bradycardia · Sinus Node Disease · Atrio-ventricular Block
Primary: Percentage of Patients in Whom ACap™ Confirm Algorithm is Programmed Safely to ON During the First 12 Months. — 61.9 percentage of patients
Pulmonary Disease, Chronic Obstructive
Primary: Area Under the Curve Calculated From 0 to 4 Hours (AUC[0-4hr]) Specific Conductance (sGaw) After the Morning Dose of Study Medication at Day 28 of Each Treatment Period…